Generate Biomedicines, Inc. (GENB)
NASDAQ: GENB · Real-Time Price · USD
19.88
+2.16 (12.19%)
Aug 25, 2026, 2:31 PM EDT - Market open
Generate Biomedicines Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Generate Biomedicines stock has a consensus rating of "Strong Buy" and an average price target of $25.6. The average 1-year stock price forecast is 28.77% higher than the current stock price, while the lowest is $22 (+10.66%) and the highest is $30 (+50.91%).
Price Target: $25.6 (+28.77%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Generate Biomedicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Aug '26 |
|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Buy Reiterates $22 | Buy | Reiterates | $22 | +10.66% | Aug 17, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $24 | Buy | Reiterates | $24 | +20.72% | Aug 7, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $25 | Buy | Reiterates | $25 | +25.75% | Aug 7, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $30 | Buy | Reiterates | $30 | +50.91% | Jun 25, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $26 | Buy | Maintains | $26 | +30.78% | Apr 10, 2026 |
Financial Forecast
Revenue This Year
29.68M
from 31.89M
Decreased by -6.93%
Revenue Next Year
23.83M
from 29.68M
Decreased by -19.71%
EPS This Year
-2.30
EPS Next Year
-2.28
from -2.30
EPS and Forward PE are based on non-GAAP adjusted numbers.